Travere Therapeutics (TVTX) Short Interest Ratio & Short Volume → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free TVTX Stock Alerts $6.82 +0.07 (+1.04%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Travere Therapeutics Short Interest DataCurrent Short Volume11,800,000 sharesPrevious Short Volume10,600,000 sharesChange Vs. Previous Month+11.32%Dollar Volume Sold Short$74.58 millionShort Interest Ratio / Days to Cover9.9Last Record DateApril 15, 2024Outstanding Shares76,110,000 sharesPercentage of Shares Shorted15.50%Today's Trading Volume1,229,505 sharesAverage Trading Volume1,282,253 sharesToday's Volume Vs. Average96% Short Selling Travere Therapeutics ? Sign up to receive the latest short interest report for Travere Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTVTX Short Interest Over TimeTVTX Days to Cover Over TimeTVTX Percentage of Float Shorted Over Time Ad True Market InsidersExposed: 10 CENT Crypto to Explode May 20th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 Travere Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202411,800,000 shares $74.58 million +11.3%N/A9.9 $6.32 3/31/202410,600,000 shares $81.73 million +5.3%N/A8.8 $7.71 3/15/202410,070,000 shares $75.42 million -1.9%N/A8.2 $7.49 2/29/202410,260,000 shares $77.57 million +5.1%N/A7.5 $7.56 2/15/20249,760,000 shares $85.30 million -1.7%N/A6.7 $8.74 1/31/20249,930,000 shares $88.67 million +2.3%N/A6.3 $8.93 Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20249,710,000 shares $92.54 million -2.1%N/A5.8 $9.53 12/31/20239,920,000 shares $89.18 million +2.9%N/A5.9 $8.99 12/15/20239,640,000 shares $83.48 million -3.1%N/A5.8 $8.66 11/30/20239,950,000 shares $62.49 million -6.7%N/A5 $6.28 11/15/202310,660,000 shares $65.77 million +21.0%N/A5.9 $6.17 10/31/20238,810,000 shares $57.09 million +0.5%N/A5.2 $6.48 10/15/20238,770,000 shares $62.27 million +4.2%N/A5.6 $7.10 9/30/20238,420,000 shares $75.27 million -6.9%N/A5.8 $8.94 9/15/20239,040,000 shares $123.76 million +5.7%N/A6.7 $13.69 8/31/20238,550,000 shares $122.09 million +5.6%N/A8.3 $14.28 8/15/20238,100,000 shares $123.12 million +0.4%N/A7.6 $15.20 7/31/20238,070,000 shares $138.72 million -2.7%N/A7.3 $17.19 7/15/20238,290,000 shares $126.92 million -2.5%N/A6.5 $15.31 6/30/20238,500,000 shares $130.56 million +11.0%N/A6.3 $15.36 6/15/20237,660,000 shares $131.75 million +4.9%N/A5.4 $17.20 5/31/20237,300,000 shares $130.60 million -3.2%N/A5.4 $17.89 5/15/20237,540,000 shares $123.20 million -4.1%N/A4.7 $16.34 4/30/20237,860,000 shares $169.54 million -3.7%N/A4.7 $21.57 4/15/20238,160,000 shares $165.81 million -4.5%N/A5.6 $20.32 3/31/20238,540,000 shares $192.06 million +14.8%N/A5.7 $22.49 3/15/20237,440,000 shares $158.25 million -1.6%N/A5.4 $21.27 2/28/20237,560,000 shares $167.53 million +9.9%N/A5.7 $22.16 2/15/20236,880,000 shares $138.43 million -7.7%N/A5.8 $20.12 1/31/20237,450,000 shares $166.88 million -0.9%N/A8.8 $22.40 1/15/20237,520,000 shares $152.81 million -10.3%N/A9.1 $20.32 12/30/20228,380,000 shares $176.23 million +3.1%N/A10 $21.03 12/15/20228,130,000 shares $150.41 million -1.2%N/A9.7 $18.50 11/30/20228,230,000 shares $165.67 million +5.9%N/A10.6 $20.13 11/15/20227,770,000 shares $167.13 million -1.2%N/A10.4 $21.51 10/31/20227,860,000 shares $170.40 million +23.0%13.0%10.9 $21.68 10/15/20226,390,000 shares $132.15 million -6.2%10.6%8.4 $20.68 9/30/20226,810,000 shares $167.80 million +3.0%11.3%10.3 $24.64 9/15/20226,610,000 shares $179.79 million -0.5%11.0%9.9 $27.20 8/31/20226,640,000 shares $177.69 million -10.2%11.1%9 $26.76Elon Musk Secret Crypto Plot Exposed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. TVTX Short Interest - Frequently Asked Questions What is Travere Therapeutics' current short interest? Short interest is the volume of Travere Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 11,800,000 shares of TVTX short. Learn More on Travere Therapeutics' current short interest. What is a good short interest ratio for Travere Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TVTX shares currently have a short interest ratio of 10.0. Learn More on Travere Therapeutics's short interest ratio. Which institutional investors are shorting Travere Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Travere Therapeutics: Capstone Investment Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Travere Therapeutics' short interest increasing or decreasing? Travere Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 11,800,000 shares, an increase of 11.3% from the previous total of 10,600,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Travere Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Travere Therapeutics: KalVista Pharmaceuticals, Inc. (13.80%), Altimmune, Inc. (28.73%), Oculis Holding AG (0.13%), Shattuck Labs, Inc. (4.42%), Verve Therapeutics, Inc. (28.64%), Larimar Therapeutics, Inc. (5.69%), Adlai Nortye Ltd. (0.02%), COMPASS Pathways plc (5.39%), Arbutus Biopharma Co. (2.74%), Astria Therapeutics, Inc. (11.33%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Travere Therapeutics stock? Short selling TVTX is an investing strategy that aims to generate trading profit from Travere Therapeutics as its price is falling. TVTX shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Travere Therapeutics? A short squeeze for Travere Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TVTX, which in turn drives the price of the stock up even further. How often is Travere Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TVTX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: KalVista Pharmaceuticals Short Interest Data Altimmune Short Interest Data Oculis Short Interest Data Shattuck Labs Short Interest Data Verve Therapeutics Short Interest Data Larimar Therapeutics Short Interest Data Adlai Nortye Short Interest Data COMPASS Pathways Short Interest Data Arbutus Biopharma Short Interest Data Astria Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TVTX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsHow Biden has already won 2024Porter & Company